KRAS and neoplasm: MPE is a relatively new field of research, thus analyses are often exploratory and need confirmation from other studies.1 Not all patients with available tumour tissue samples could be included in the subtype analyses: MSI status was available for 90% of cases, BRAF for 92%, KRAS for 92% and CIMP for 99% of cases.